An interventional study of Annual PSA Health Maintenance Reminder in Prostate Cancer and Cancer of the Prostate, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to male participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Prostatic Neoplasms by Washington University School of Medicine — 9 open to participants now, 11 under way, none of them phase 3. Prostatic Neoplasms · Washington University School of Medicine.
Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, this one has the largest planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 12 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 18th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 23 studies in Prostatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 40 Years to 75 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4
First in 2000; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40,000 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 35 across the 20 interventional studies, 1,019 across the 2 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
3 of the studies in Prostatic Neoplasms by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04354064Washington University School of MedicineCirculating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | 2026-12-31 |
| NCT04420702Washington University School of MedicineDiffusion Basis Spectrum Imaging of the Prostate | 2027-05-31 |
| NCT00937586Washington University School of MedicineProstate Cancer Prospective Cohort | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care:
Eligibility Criteria:
Meet one of the following risk criteria:
High Risk for Prostate Cancer
Average Risk for Prostate Cancer
An annual health maintenance reminder will be implemented for all men who meet the American Cancer Society guidelines for average- and high-risk eligibility criteria. The goal is to encourage their primary care provider (PCP) to engage in a shared decision-making discussion with the patient about the benefits and risks of prostate cancer screening. This alert will appear in the health maintenance reminder section of the electronic health record (EHR). Although all providers with access to EPIC can view the alert, it is typically the PCPs who review and take action on alerts in the health maintenance reminder section.
Other: Annual PSA Health Maintenance Reminder
The annual health maintenance reminder does not mandate PSA screening for eligible patients. Instead, it recommends that primary care providers (PCPs) initiate a shared decision-making discussion with their patients. As part of this conversation, patients will be informed of their individual risk factors-including race, family history, and germline mutations-and can then make an informed choice about whether to proceed with PSA screening.
Change in PSA screening completion rates in the BJC East Health System
The overall PSA screening rate will be calculated as the number of PSA screening tests that are ordered by PCPs who will receive the alert and completed by patients within a year of the ordering date, divided by the total number of eligible patients.
Time frame: Through 5 years
Proportion of men diagnosed with clinically significant prostate cancer (Gleason score ≥ 7)
Time frame: Through 5 years
Incidence of advanced and metastatic disease at diagnosis of prostate cancer
Time frame: Through 5 years
Incidence of early-stage prostate cancer
Time frame: Through 5 years
Stage distribution of prostate cancer diagnoses
Time frame: Through 5 years
Biopsy rates
Time frame: Through 5 years
Percent of PSA screening ordered but not completed
Time frame: Through 5 years
Median PSA at time of diagnosis
Time frame: Through 5 years
Evaluate the agreement between 3T MRI and biomarker test results
The 3T MRI and biomarker tests are used to help determine whether a biopsy is necessary. The investigators will categorize the results as positive versus negative and the agreement will be gauged based on Kappa coefficient.
Time frame: Through 5 years
PSA screening rate by age group
Age groups will include 40-49, 50-70, and 70-75
Time frame: Through 5 years
PSA screening rate by race
Time frame: Through 5 years
PSA screening rate by comorbidity burden
Time frame: Through 5 years
PSA screening rate by insurance coverage
Time frame: Through 5 years
PSA screening rate by provider
Time frame: Through 5 years
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Aug 2031, 72 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 72 months is above that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →